DEF: Biofrontera Seeks Reverse Split, Preferred Stock Approvals

Biofrontera Inc. is seeking stockholder approval for a reverse stock split to maintain Nasdaq listing and to enable full conversion and voting rights for recently issued Series C and Series D Preferred Stock.

Summary

• A Special Meeting of Stockholders will be held on September 16, 2025, at 10:00 a.m. Eastern Time, in a virtual-only format.
• Stockholders will vote on four proposals: a reverse stock split, approval of Series C Preferred Stock conversion and voting rights, approval of Series D Preferred Stock conversion and voting rights, and an adjournment proposal.
• The proposed reverse stock split ratio is between 1-for-3 and 1-for-8, at the Board's discretion, aimed at regaining compliance with Nasdaq's minimum $1.00 bid price requirement.
• The company received a Nasdaq notice on May 8, 2025, for non-compliance, with a deadline to regain compliance by November 5, 2025.
• The Series C Preferred Stock offering involved issuing up to 11,000 shares at $1,000 per share, totaling $11.0 million, to fund operations and satisfy financial obligations.
• As of August 1, 2025, 8,500 shares of Series C Preferred Stock have been issued.
• The Series D Preferred Stock, consisting of 3,019 shares, was issued to Biofrontera AG as part of a strategic transaction to acquire U.S. rights to Ameluz and RhodoLED.
• Both Series C and D Preferred Stock have a conversion price of $0.6249 per share of Common Stock.
• As of July 18, 2025, 10,138,567 shares of Common Stock were outstanding, and 20,753 shares of Preferred Stock were outstanding.
• If approved, the conversion of Series C and D Preferred Stock could result in the issuance of an additional 18,433,349 shares of Common Stock (13,602,176 from Series C and 4,831,173 from Series D).
• The Board of Directors unanimously recommends voting FOR all four proposals.

Sentiment

Score: 4

Explanation: The filing addresses critical issues (Nasdaq delisting risk, financing, strategic transaction) but highlights significant potential dilution and the inherent risks of a reverse stock split. While the strategic transaction and financing are positive, the need for these actions stems from underlying challenges (low stock price, financial obligations). The Board's recommendation for approval is based on necessity rather than strong positive performance.

Positives

• The strategic transaction to acquire U.S. rights to Ameluz and RhodoLED from Biofrontera AG is expected to streamline operations and maximize product value.
• The Series C Preferred Offering provides $11.0 million in necessary financing for continued operations and to satisfy financial obligations.
• Maintaining Nasdaq listing is crucial for the company's ability to access capital markets, pursue acquisitions, and enhance the liquidity and marketability of its common stock.

Negatives

• The reverse stock split may not guarantee a sustained increase in stock price or improved liquidity, and some investors may view it negatively.
• The reverse stock split could result in stockholders owning 'odd lots' (fewer than 100 shares), which may be more difficult to sell and incur higher transaction costs.
• The potential issuance of 18,433,349 additional shares of Common Stock upon conversion of Series C and D Preferred Stock represents significant dilution for existing common stockholders.
• Failure to approve the Series C and D proposals would limit the conversion and voting rights of preferred stockholders and impose restrictions on various company actions, including material business changes, issuing senior equity, paying dividends, and certain transactions.
• If the Series C and D proposals are not approved, the company will incur significant expenses and management distraction from semi-annual re-submissions for stockholder approval.

Risks

• Risk of delisting from Nasdaq if the common stock's closing bid price does not meet the $1.00 minimum requirement by November 5, 2025, or any extended compliance period.
• Delisting could adversely affect the trading market for the common stock, impair the company's ability to access capital markets, and hinder future acquisitions.
• There is no assurance that the reverse stock split will sufficiently increase the stock price or be completed before Nasdaq initiates delisting procedures.
• The stock price after a reverse split may not increase proportionally to the reduction in shares, potentially leading to a decrease in overall market capitalization.
• The stock price may decline due to various factors, including future performance and general industry, market, and economic conditions, even after a reverse split.
• The liquidity of the common stock may be negatively impacted by the reduced number of shares outstanding after a reverse split.
• Failure to obtain stockholder approval for the Series C and D Preferred Stock proposals could limit the company's ability to issue preferred stock in satisfaction of obligations and raise additional capital.

Future Outlook

The Board intends to monitor the common stock's closing bid price and may choose not to effect the reverse stock split if the company regains Nasdaq compliance naturally. However, if compliance is subsequently lost, the Board retains the discretion to implement the reverse split. The authority granted to the Board for the reverse split will terminate one year after stockholder approval if not utilized. If the Series C and D Preferred Stock proposals are not approved, the company is obligated to resubmit them for stockholder approval at least semi-annually until obtained.

Management Comments

• "The Board considers it important for the Company to maintain its Nasdaq listing. Delisting could adversely affect the trading market for the Common Stock. Further, delisting would adversely affect the Company’s ability to access the capital markets or pursue acquisitions."
• "The primary goal of the Reverse Split is to increase the per share market price of our Common Stock to meet and maintain the minimum per share bid price requirements for continued listing on Nasdaq."
• "There is no guarantee that the price of the Company’s Common Stock will be sufficient to meet the minimum bid price requirement, even if there are positive business developments in the near future that could result in an increase in the trading price of our Common Stock in the next few months."
• "The Board intends to monitor the closing bid price of its Common Stock before effecting the Reverse Stock Split. If, based on the bid price of the Company’s Common Stock closing at or above $1.00 per share for a minimum of 10 consecutive trading days, the Company achieves compliance with the minimum bid price requirement prior to effecting the Reverse Split, the Board does not intend to effect the Reverse Split."
• "The process of continuing to hold stockholder meetings to obtain the requisite stockholder approval would cause us to incur significant expenses and would divert our management’s attention from the operation of our business, which could materially harm our business."

Industry Context

This filing primarily addresses corporate finance and governance issues specific to Biofrontera Inc. and its relationship with its former parent, Biofrontera AG. The acquisition of U.S. rights to Ameluz and RhodoLED signifies a strategic move to consolidate control over key dermatology products, a common trend in the pharmaceutical/biotech industry for companies aiming to streamline operations and maximize product value. The necessity for a reverse stock split is a frequent challenge for smaller biotech companies listed on Nasdaq, often indicating a need to meet exchange listing requirements and improve stock marketability.

Comparison to Industry Standards

• Reverse stock splits are a common strategy employed by small-cap companies, particularly in the biotech and technology sectors, to regain compliance with stock exchange minimum bid price requirements, such as Nasdaq's $1.00 threshold.
• The issuance of preferred stock for strategic acquisitions and financing is a standard practice, especially when common equity raises are challenging due to low stock prices or unfavorable market conditions, as seen with the Series C and D Preferred Stock issuances.
• The 19.99% cap on preferred stock conversion and voting rights without prior shareholder approval is a direct measure to comply with Nasdaq Listing Rule 5635, a standard rule governing equity issuances that exceed certain thresholds.
• The royalty structure (12% below $65 million, 15% above) for Ameluz revenue, as part of the U.S. rights acquisition, is a typical financial arrangement found in licensing and acquisition agreements within the pharmaceutical industry, designed to align incentives and share future revenue streams.

Corporate Governance

Related Party Transactions

• The company signed an agreement with its former parent company, Biofrontera AG, and its subsidiaries to acquire all U.S. rights to Ameluz and RhodoLED (the Strategic Transaction).
• As part of the Strategic Transaction, Biofrontera AG will receive 3,019 shares of Series D Convertible Preferred Stock, representing a 10% equity stake on a fully-diluted basis.
• The company will pay a royalty to Biofrontera AG (12% for Ameluz revenue below $65.0 million, 15% above $65.0 million), replacing a previous transfer pricing model.
• The Series C Preferred Offering was partly to satisfy certain financial obligations to Biofrontera AG that originated from a prior license and supply agreement.
• Heikki Lanckriet, a director of Biofrontera Inc., is also a director of Biofrontera AG.

Stakeholder Impact

• Shareholders: Potential for increased stock price and improved marketability if reverse split is successful, but also significant dilution from preferred stock conversions. Risk of delisting if proposals fail. Fractional shares will be rounded up to a full share.
• Employees: No direct impact mentioned, but continued Nasdaq listing and financial stability are generally positive for employee morale and retention.
• Customers: No direct impact mentioned, but the acquisition of U.S. rights to Ameluz and RhodoLED aims to consolidate control over key products, potentially ensuring continued availability and support.
• Suppliers: No direct impact mentioned.
• Creditors: Improved financial stability and access to capital markets (if Nasdaq listing is maintained) could be viewed positively by creditors.

Next Steps

• Hold a Special Meeting of Stockholders on September 16, 2025, to vote on the proposed amendments and issuances.
• If the Reverse Split Proposal is approved, the Board has the discretion to effect the reverse stock split prior to the one-year anniversary of the approval date.
• If the Series C or Series D Proposals are not approved, the company is required to submit them for stockholder approval at least semi-annually until approval is obtained.
• Announce preliminary voting results at the Special Meeting and publish final results in a Current Report on Form 8-K with the SEC.

Key Dates

Recommendation

The company is undertaking critical actions to address its Nasdaq listing compliance and secure necessary financing through preferred stock issuances and a strategic asset acquisition. While these steps are essential for the company's continued operations and market presence, the significant potential dilution from the preferred stock conversions and the inherent uncertainty of a reverse stock split's long-term impact on stock price introduce considerable risk. Investors should hold to observe the outcome of the stockholder meeting and the company's ability to execute its strategy post-approvals, particularly regarding the integration of the acquired U.S. rights and future financial performance. The current low stock price and the need for these measures indicate underlying challenges that require careful monitoring.

Keywords

Biofrontera, BFRI, Reverse Stock Split, Nasdaq Listing, Preferred Stock, Series C Preferred, Series D Preferred, Stockholder Vote, Corporate Governance, Dilution, Capital Raise, Ameluz, RhodoLED, Pharmaceutical, Biotech